Michael Andreeff Selected Research

Cytarabine (Cytosar-U)

11/2022	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
1/2021	BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
1/2021	DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
1/2021	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
1/2019	BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment.
10/2018	Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
4/2018	Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.
1/2018	Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
1/2017	Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia.
1/2017	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Andreeff Research Topics

Disease

160	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2022 - 01/2002
120	Neoplasms (Cancer) 02/2022 - 01/2002
103	Leukemia 01/2022 - 02/2002
18	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2022 - 06/2002
17	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2002
17	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2019 - 06/2002
16	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2002
16	Hematologic Neoplasms (Hematological Malignancy) 03/2021 - 01/2002
16	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2020 - 04/2002
15	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 06/2002
13	Hypoxia (Hypoxemia) 01/2020 - 08/2009
11	Acute Promyelocytic Leukemia 01/2022 - 03/2004
10	Carcinogenesis 01/2022 - 09/2003
10	Lymphoma (Lymphomas) 01/2015 - 10/2004
8	Philadelphia Chromosome 10/2011 - 04/2002
6	Blast Crisis (Blast Phase) 10/2015 - 02/2006
5	Inflammation (Inflammations) 10/2019 - 03/2006
5	Myeloid Leukemia (Leukemia, Myelocytic) 01/2017 - 01/2002
5	Glioma (Gliomas) 04/2013 - 04/2005
5	Mitochondrial Diseases (Mitochondrial Disease) 05/2008 - 12/2005
4	Disease Progression 01/2022 - 06/2008
4	AIDS-Related Complex (ARC) 01/2019 - 01/2011
4	Residual Neoplasm 01/2018 - 01/2017
4	Pancreatic Neoplasms (Pancreatic Cancer) 09/2010 - 10/2002
3	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 10/2018
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 03/2003
3	Exanthema (Rash) 01/2021 - 04/2014
3	Fatigue 01/2021 - 09/2006

Drug/Important Bio-Agent (IBA)

66	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2002
27	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2022 - 04/2002
22	venetoclaxIBA 11/2022 - 03/2014
20	TriterpenesIBA 11/2014 - 01/2002
15	bardoxoloneIBA 04/2012 - 01/2002
14	Sorafenib (BAY 43-9006)FDA Link 11/2020 - 02/2008
14	Pharmaceutical PreparationsIBA 12/2017 - 09/2003
12	LigandsIBA 11/2021 - 07/2002
12	Phosphotransferases (Kinase)IBA 01/2021 - 06/2003
12	bardoxolone methylIBA 11/2014 - 01/2002
11	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 07/2002
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2018 - 05/2002
10	CaspasesIBA 11/2014 - 12/2002
10	SurvivinIBA 08/2013 - 09/2003
10	AcidsIBA 11/2007 - 09/2003
9	Tyrosine Kinase InhibitorsIBA 04/2022 - 06/2003
9	Azacitidine (5 Azacytidine)FDA Link 01/2022 - 06/2013
9	Biological ProductsIBA 01/2022 - 07/2002
9	Oxygen (Dioxygen)IBA 10/2021 - 07/2008
9	ABT-737IBA 09/2021 - 11/2006
9	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018 - 06/2006
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2002
8	CytokinesIBA 01/2020 - 09/2002
8	fms-Like Tyrosine Kinase 3IBA 12/2017 - 04/2006
7	Fatty Acids (Saturated Fatty Acids)IBA 01/2020 - 03/2009
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2017 - 04/2005
7	bcr-abl Fusion ProteinsIBA 01/2016 - 07/2002
7	fludarabineIBA 07/2015 - 04/2002
6	EnzymesIBA 01/2022 - 01/2009
6	Decitabine FDA Link 01/2022 - 08/2003
6	Transcription Factors (Transcription Factor)IBA 01/2021 - 03/2006
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 02/2006
6	MicroRNAs (MicroRNA)IBA 01/2018 - 03/2008
6	Messenger RNA (mRNA)IBA 01/2018 - 06/2002
6	nutlin 3IBA 01/2017 - 08/2006
5	NF-kappa B (NF-kB)IBA 01/2022 - 01/2002
5	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 06/2009
5	selinexorIBA 11/2020 - 01/2015
5	Adenosine Triphosphate (ATP)IBA 01/2013 - 12/2002
5	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2012 - 08/2005
5	EstersIBA 12/2010 - 01/2002
5	PPAR gammaIBA 06/2010 - 07/2002
4	MethyltransferasesIBA 01/2021 - 06/2009
4	Galectin 3 (LGALS3)IBA 06/2019 - 04/2016
4	Rituximab (Mabthera)FDA Link 01/2019 - 05/2003
4	CateninsIBA 01/2019 - 04/2014
4	ChemokinesIBA 04/2016 - 12/2006
4	ProdrugsIBA 04/2016 - 01/2011
4	Bortezomib (Velcade)FDA Link 02/2016 - 10/2003
4	Cyclin D1IBA 01/2015 - 09/2003
4	Monoclonal AntibodiesIBA 03/2014 - 06/2005
4	Caspase 8 (Caspase-8)IBA 02/2014 - 05/2005
4	Antisense OligonucleotidesIBA 08/2013 - 02/2009
4	Chemokine CXCL12IBA 01/2013 - 04/2005
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2012 - 04/2002
4	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2010 - 04/2005
4	Mitogen-Activated Protein KinasesIBA 03/2010 - 05/2002
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2008 - 09/2002
4	promyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinIBA 12/2007 - 03/2004
3	Radioisotopes (Radionuclides)IBA 02/2022 - 01/2018
3	GD2 gangliosideIBA 01/2022 - 06/2012
3	VaccinesIBA 01/2022 - 04/2003
3	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 12/2011
3	NucleophosminIBA 01/2021 - 12/2013
3	Drug CombinationsIBA 01/2021 - 05/2014

Therapy/Procedure

88	Therapeutics 05/2022 - 04/2002
42	Drug Therapy (Chemotherapy) 01/2022 - 03/2003
5	Induction Chemotherapy 01/2022 - 03/2003
4	Transplantation 01/2022 - 01/2012
4	Radiotherapy 01/2021 - 08/2004
4	Stem Cell Transplantation 01/2018 - 12/2011
3	Immunotherapy 01/2022 - 04/2003